Methylation Status of the RB1 Gene as a Diagnostic and Prognostic Tool in Breast Cancer: Correlations with Clinicopathological Features and Immunohistochemical Markers
DOI:
https://doi.org/10.36320/ajb/v17.i2.19291Keywords:
Breast Cancer, RB1 Gene, Ki-67, TNBCAbstract
Abstract:
Background
The RB1 gene plays important role in regulating the cell cycle and has been implicated in various malignancies, including breast cancer. Methylation-specific PCR (MSP) was used to assess RB1 methylation, while immunohistochemical markers such as ER, PR, HER2, and Ki-67 were analyzed to correlate molecular changes with clinical characteristics. The findings demonstrate that aberrant RB1methylation is significantly linked to more aggressive tumor phenotypes, including higher histologic grade, advanced stage, and elevated Ki-67 expression. Furthermore, RB1 methylation status correlated with poor survival outcomes, suggesting its role as a prognostic biomarker. This study underscores the importance of RB1 methylation in breast cancer pathophysiology and its potential clinical utility.
Method
A total of 40 primary breast carcinoma tissue samples and 10 non-neoplastic breast tissue samples were collected from the pathology archives of medical institutions in Duhok, Iraq. Clinical and pathological data, including patient age, tumor size, stage, and grade, were retrieved from medical records. Hematoxylin and Eosin (H&E) staining was performed to confirm diagnosis. Immunohistochemical (IHC) staining was conducted for Ki-67, ER, PR, and HER2, while MSP was employed to evaluate RB1 methylation and its association with clinical parameters.
Results
All patients in this study were female, with 70% being over 50 years old. Immunohistochemical analysis revealed that ER, PR, and HER2 were negative in 65%, 70%, and 60% of cases, respectively, while 70% of tumors exhibited high Ki-67 expression. A significant correlation was found between Ki-67 expression and receptor status, as well as other clinicopathological features. RB1 methylation was identified in 24 cases (60%), demonstrating a strong association with tumor aggressiveness and immunohistochemical markers.
Conclusion
The study confirms the association between RB1 methylation and breast cancer progression. Evaluating RB1 methylation status could provide valuable diagnostic and prognostic insights, potentially guiding targeted therapeutic strategies.
Downloads
References
References
1. Pankotai-Bodo G, Orsolya N, Farkas S, Tibor P (2024). Routine molecular applications and recent advances in breast cancer diagnostics. Journal of Biotechnology. Journal of Biotechnology; 380:20–28. DOI: 10.1016/j.jbiotec.2023.12.005.
2. Wang Y, Yang R, Liu R, Yang R, Lin Z and He A (2024) The significance of RB1 in multiple myeloma. Frontiers in Immunology; 15:1415972. DOI: 10.3389/fimmu.2024.1415972
3. Vietri M, Giovanna D, Giuditta B, Giuseppe F, Gemma C, Giovanni N et al (2021). DNA methylation and breast cancer: A way forward (Review). INTERNATIONAL JOURNAL OF ONCOLOGY; 59: 98. https://doi.org/10.3892/ijo.2021.5278
4. Janostiak R, Torres-Sanchez A, Posas F, Nadal E. (2022). Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies. Cancers; 14, 1265. DOI: 10.3390/cancers14051265
5. Zagami P and Carey L (2022). Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer ; 8:95. DOI: 10.1038/s41523-022-00468-0
6. Janghee L, Young-jin L, Soong J, Seung B, Yoowon K, Yoon J et al (2023). Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients with Breast Cancer JAMA Network Open;3;6(8):e2330961. doi: 10.1001/jamanetworkopen.2023.30961
7. Witkiewicz A, Sejin C, Rachel B, Paris V, Jorge F, Christopher L et al (2018). Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell Rep. 2018 y 30; 22(5): 1185–1199. doi: 10.1016/j.celrep.2018.01.022
8. Gandhi R, Patil M, Swapnil K, Sagar M (2023). Ki-67 EXPRESSION IN TRIPLE NEGATIVE BREAST CANCER-APROGNOSTIC MARKER. International Journal of Academic Medicine and Pharmacy. Int J Acad Med Pharm; 5(4); 1165-1170
9. SIPPL C, URBSCHAT S, YOO J, SEBASTIAN S, JOACHIM O and RALF K (2018). Promoter methylation of RB1, P15, P16, and MGMT and their impact on the clinical course of pilocytic astrocytomas. ONCOLOGY LETTERS;15: 1600-1606, 2018. DOI: 10.3892/ol.2017.7490
10. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R and Stanisławek A (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers; 13:4287. doi: 10.3390/cancers13174287
11. Hosseini MS, Arab M, Honar BN, Noghabaei G, Safaei N, Ghasemi T et al (2013). Age – specific incidence rate change at breast cancer and its different histopathologic subtypes in Iran and Western countries. Pakistan Journal of Medical Science; 29(6): 1354-1357. DOI: 10.12669/pjms.296.3788
12. Sutton Th , Phil R , Nathalie J, Jennifer R (2018). Breast cancer in women under 50: Most are not high risk. The American Journal of Surgery; 215(5): 848-851. DOI: 10.1016/j.amjsurg.2018.01.003
13. Yun Y, Heung K, Kyung H, Kwan I and Yong S (2016). Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer J Breast Cancer;19(2): 163-168. DOI: 10.4048/jbc.2016.19.2.163
14. Mohsin RN and Mohamad BJ (2024). Clinical and Histopathological Features of Breast Cancer in Iraqi Patients between 2018-2021. Iraqi Journal of Science;65(1):90-107. DOI:10.24996/ijs.2024.65.1.9
15. Mohammed D, Mohammed R, Alwan A and Hussein R (2019). Immunohistochemical assessment of estrogen, progesterone receptors and HER2/neu overexpression by core needle biopsy in a sample of Iraqi breast cancer patients. Journal of Contemporary Medical Sciences;4(4): 214–221. DOI: https://doi.org/10.22317/jcms.v5i4.659
16. Alqaisi A, Chen L, Romond E, Chambers M (2014). Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Research Treatment;148: 437-444. DOI: 10.1007/s10549-014-3145-x
17. Alwan AS., Furat N. and Faisal H (2018). Breast Cancer Subtypes among Iraqi Patients: Identified by Their ER, PR and HER2 Status. Journal of the Faculty of Medicine Baghdad.;59(4). DOI: https://doi.org/10.32007/jfacmedbagdad.59469
18. Mandigo A, Scott A, William K, Knudsen K (2022). Relevance of pRB Loss in Human Malignancies. Clinical Cancer Research; 28:255–64. DOI: 10.1158/1078-0432.CCR-21-1565
19. Knudsen S , Steven C , Hershberger A, Agnieszka K , David W (2019). Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. Trends in cancer;5(5): 308-324. DOI: 10.1016/j.trecan.2019.03.005
20. Chinh H, Hong D, Nguyen T, Sy A, Cuong N et al (2021). Clinical evaluation of RB1 genetic testing reveals novel mutations in Vietnamese patients with retinoblastoma. MOLECULAR AND CLINICAL ONCOLOGY;15: 182. DOI: 10.3892/mco.2021.2344
21. Dyson N (2016). RB1: a prototype tumor suppressor and an enigma. GENES & DEVELOPMENT.2016;30:1492–1502. doi: 10.1101/gad.282145.116
22. Newton E, Mueller L, Treadwell M, Morris, C, Machado H (2022). Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand? Cancers;14, 482. DOI: 10.3390/cancers14030482
23. Huang M, Wang Y, Chou Y, Lee D (2024). Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy. Cancers; 16:1558. DOI: 10.3390/cancers16081558
24. Lehmann, U (2024). Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges. Cancers; 16:2164. DOI: 10.3390/cancers16122164
25. Putra M, Dedy H, Endi T, Putri C (2024). The Relationship Between KI67 Expression and Grading with Chemotherapy Response in Triple-Negative Breast Cancer Patients at Haji Adam Malik General Hospital, Med Arch;78(4):285-289. DOI: 10.5455/medarh.2024.78.285-289
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Zihel Hussein
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
